Aleutian Therapeutics, Inc.

Aleutian Therapeutics, Inc. is a corporate entity located in Los Angeles, California, registered as a minority-owned, for-profit organization specializing in advanced biotechnology research focused on regenerative medicine and cell therapy technologies. The company is registered in SAM.gov until November 19, 2025, and focuses on developing innovative therapeutic approaches for complex medical conditions, with a particular emphasis on type 1 diabetes and immune system-related challenges in cell replacement therapies. As a research-driven biotechnology firm, Aleutian Therapeutics primarily engages with federal agencies through competitive grant awards to advance cutting-edge scientific research and develop novel gene editing platforms for potential medical treatments.

The company has received multiple federal grant awards from prestigious research institutions, specifically the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of Allergy and Infectious Diseases (NIAID). These grants, totaling approximately $984,013, support research into developing immune-evasive stem cell lines and gene editing technologies for cell replacement therapies. The specific research projects include developing an immune-evasive stem cell line for type 1 diabetes regenerative therapy, creating a gene editing platform to enable allogeneic pluripotent stem cell therapies that can evade host immune system recognition, and exploring immune evasion strategies for allogeneic cell replacement treatments. Each project aims to overcome significant medical challenges such as immune rejection in stem cell therapies, with potential applications in treating conditions like type 1 diabetes, and demonstrating the ability to develop cell therapies that can survive in fully immune-competent environments without requiring chronic immunosuppression.